Trial Profile
A phase II randomized study to investigate Espranor (rapidly dissolving oral lyophilisate formulation of buprenorphine)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine
- Indications Opioid-related disorders
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 05 May 2017 According to a Martindale Pharma media release, results from this trial have been published in European Addiction Research.
- 05 May 2017 Results published in a Martindale Pharma media release.